Nail polish makers Estee lauder and Procter & Gamble reformulate nail polishes--take DBP pthalate out amid health concerns
FDA Grants Fast Track Designation to Cannabis Withdrawal Syndrome Therapy
A dose response is observed with the highest dose of the drug and mitigating withdrawal symptoms for patients with cannabis use disorder.
Episode 8: Stay in Sync with Innovations in Medication Decision Support
Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.
FDA Grants Fast Track Designation to Amlenetug As Treatment for Multiple System Atrophy
The designation is based on the AMULET phase 2 trial, which was the first-in-human study of the drug.
FDA Grants Fast Track Designation to Troculeucel for Moderate Alzheimer Disease
Data has shown the investigational cell therapy is well-tolerated in patients and showed preliminary impacts on cognition.
FDA Grants ADI-001 Fast Track Designation as Treatment of Refractory Systemic Lupus Erythematosus
ADI-001 is an investigation allogeneic gamma delta chimeric antigen receptor T cell therapy that targets CD20 for the treatment of a variety of autoimmune diseases.
FDA Grants ABO-101 Orphan Drug, Rare Pediatric Disease Designations for PH1
Primary hyperoxaluria type 1 (PH1) is a rare genetic condition that affects the kidney, bladder, or urinary tract, and indicates high levels of oxalates in the urine.